Effects of tumor necrosis factor-alpha in vitro on steroidogenesis of healthy and atretic follicles of the rat: theca as a target.
Tumor necrosis factor-alpha (TNF), a pleiotropic cytokine localized within the ovary, alters follicular steroidogenesis. Preovulatory follicles dissected from ovaries of normal cyclic adult rats on the morning of proestrus exhibit steroidogenic and histological signs of atresia after 24 h of culture under the conditions of 5% CO2 and air. Follicles cultured for 24 h in 5% CO2 and 95% O2 appeared histologically and steroidogenically healthy. Under both culture conditions, human recombinant TNF (5 ng/ml) significantly increased the production of pregnenolone, progesterone, 20 alpha-dihydroprogesterone, and 17 alpha-hydroxyprogesterone by the follicles. Follicles cultured in 5% CO2 and air exhibited no change in androstenedione or estradiol production compared to control follicles incubated without TNF. In contrast, follicles cultured in 5% CO2 and 95% O2 responded to TNF with increased androstenedione and estradiol production. Separation of the thecal and granulosa compartments indicated that the increased progestin production observed in the whole follicle in response to TNF originated from the theca. TNF significantly inhibited basal and FSH-stimulated progesterone production from the granulosa of preovulatory follicles. Exogenous substrate added to whole follicles cultured in the presence or absence of TNF indicated that TNF enhanced the conversion of 25-hydroxycholesterol to pregnenolone. These studies reveal that TNF enhanced steroidogenesis in both healthy and atretic follicles and that this action of TNF is on the theca, where TNF increases the conversion of cholesterol to pregnenolone. The data imply that TNF has differential effects on thecal and granulosa steroidogenesis.
Roby
K F
KF
Department of Physiology, University of Kansas Medical Center, Kansas City 66103.
Terranova
P F
PF
D019326:17-alpha-Hydroxyprogesterone; D004092:20-alpha-Dihydroprogesterone / Q000096:biosynthesis; D000735:Androstenedione / Q000096:biosynthesis; D000818:Animals; D002478:Cells, Cultured; D004958:Estradiol / Q000096:biosynthesis; D005260:Female; D005640:Follicle Stimulating Hormone / Q000494:pharmacology; D006107:Granulosa Cells / Q000187:drug effects / Q000378:metabolism; D006888:Hydroxycholesterols / Q000378:metabolism / Q000494:pharmacology; D006908:Hydroxyprogesterones / Q000378:metabolism / Q000494:pharmacology; D007700:Kinetics; D006080:Ovarian Follicle / Q000378:metabolism*; D010100:Oxygen / Q000008:administration & dosage / Q000494:pharmacology; D011284:Pregnenolone / Q000096:biosynthesis / Q000494:pharmacology; D011359:Proestrus; D011374:Progesterone / Q000096:biosynthesis / Q000494:pharmacology; D051381:Rats; D011994:Recombinant Proteins; D013256:Steroids / Q000096:biosynthesis*; D013799:Theca Cells / Q000187:drug effects / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D006888:Hydroxycholesterols; D006908:Hydroxyprogesterones; D011994:Recombinant Proteins; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha; D004092:20-alpha-Dihydroprogesterone; D000735:Androstenedione; D011374:Progesterone; D004958:Estradiol; D019326:17-alpha-Hydroxyprogesterone; D011284:Pregnenolone; C007997:25-hydroxycholesterol; D005640:Follicle Stimulating Hormone; D010100:Oxygen